Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion”In the company’s words, NCT05883449 on ClinicalTrials.gov
- Tested for
- Peripheral T Cell Lymphoma (2 trials), Transformed Mycosis Fungoides, Relapsed or Refractory Hodgkin Lymphoma
- Main trialPhase 2
- “This is a phase II study to evaluate the antitumor activity and safety of AFM13 given as monotherapy in patients with CD30-positive T-cell lymphoma. The investigational medicinal product AFM13 is a tetravalent bispecific chimeric (anti-human CD30 x anti-human CD16A) recombinant antibody construct which is being developed to treat CD30-positive malignancies. Patients who suffer from peripheral T-cell lymphoma or transformed mycosis fungoides, whose tumor expresses the surface marker CD30, and who have relapsed after an earlier treatment or have refractory disease will be enrolled into this…”In the company’s words, NCT04101331 on ClinicalTrials.gov
Other drugs for Peripheral T Cell Lymphoma
- XNW5004Evopoint Biosciences Inc. · Phase 3
- GolidocitinibDizal Pharmaceuticals · Phase 3
- SoquelitinibCorvus Pharmaceuticals, Inc. · Phase 3
- Liposomal mitoxantrone hydrochlorideCSPC · Phase 3
- DuvelisibSecuraBio · Phase 3
- BelinostatAcrotech Biopharma Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 11 May 2022 | Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides | |
| Phase 2Terminated | 7 Nov 2024 | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026